Lamivudine + Tenofovir Disoproxil FumarateThird Party Manufacturing in India

Lamivudine + Tenofovir Disoproxil Fumarate is a fixed-dose combination of two nucleoside analogue reverse transcriptase inhibitors that work synergistically to suppress HIV-1 replication through complementary mechanisms. Lamivudine is a cytidine analogue that undergoes intracellular phosphorylation to lamivudine triphosphate, which competes with deoxycytidine triphosphate for incorporation into viral DNA by HIV reverse transcriptase, causing chain termination and blocking viral DNA synthesis. Tenofovir Disoproxil Fumarate is a prodrug that is rapidly converted in vivo to tenofovir, an acyclic nucleoside phosphonate analogue. Tenofovir is further phosphorylated to tenofovir diphosphate, which inhibits HIV reverse transcriptase by competing with the natural substrate deoxyadenosine triphosphate and causing chain termination after incorporation into viral DNA. As a phosphonate, tenofovir bypasses the first rate-limiting phosphorylation step, resulting in higher intracellular concentrations of the active metabolite compared to other NRTIs. The combination of lamivudine and tenofovir provides a dual-NRTI backbone that forms the foundation of most first-line antiretroviral regimens. Both drugs have complementary resistance profiles, and together they create a high genetic barrier to resistance development. This combination also exhibits activity against hepatitis B virus, with both lamivudine and tenofovir demonstrating independent anti-HBV effects, making it particularly valuable in co-infected patients.

Therapeutic Uses

Lamivudine + Tenofovir Disoproxil Fumarate is prescribed for the treatment of:

• HIV-1 Infection: This fixed-dose combination is indicated as part of combination antiretroviral therapy for the treatment of HIV-1 infection in adults and paediatric patients, serving as the preferred dual-NRTI backbone in first-line regimens.
• Pre-Exposure Prophylaxis: Tenofovir disoproxil fumarate in combination with emtricitabine (a closely related NRTI) is approved for HIV PrEP, highlighting the importance of this drug class in HIV prevention.
• HIV-HBV Co-Infection: The combination is particularly valuable in patients co-infected with HIV and hepatitis B, as both drugs have independent anti-HBV activity, allowing simultaneous treatment of both infections.
• Post-Exposure Prophylaxis: Used as part of 28-day combination regimens for HIV PEP following occupational or sexual exposure to HIV.

Why Manufacturers Choose Lamivudine + Tenofovir Disoproxil Fumarate

The lamivudine + tenofovir DF fixed-dose combination is the most widely prescribed dual-NRTI backbone in global antiretroviral therapy and is included in all WHO-recommended first-line regimens for HIV-1 infection. Available as 200 mg + 300 mg tablets, this combination generates the highest-volume demand of any antiretroviral product category. Indian manufacturers are the world's primary suppliers of generic antiretroviral combinations, serving government tender programmes, international procurement agencies like UNITAID and the Global Fund, and institutional markets in Africa and Asia. The well-established manufacturing technology for both API and finished formulation, combined with enormous economies of scale, makes this product a cornerstone of any antiretroviral manufacturing portfolio. This makes Lamivudine + Tenofovir Disoproxil Fumarate one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.